Author
Listed:
- Jingjing Zhu
(Ludwig Institute for Cancer Research
Université Catholique de Louvain
Walloon Excellence in Life Sciences and Biotechnology)
- Céline G. Powis de Tenbossche
(Ludwig Institute for Cancer Research
Université Catholique de Louvain)
- Stefania Cané
(Ludwig Institute for Cancer Research
Université Catholique de Louvain
Walloon Excellence in Life Sciences and Biotechnology)
- Didier Colau
(Ludwig Institute for Cancer Research
Université Catholique de Louvain)
- Nicolas van Baren
(Ludwig Institute for Cancer Research
Université Catholique de Louvain)
- Christophe Lurquin
(Ludwig Institute for Cancer Research
Université Catholique de Louvain)
- Anne-Marie Schmitt-Verhulst
(Aix Marseille Université, Inserm, CNRS)
- Peter Liljeström
(Karolinska Institutet)
- Catherine Uyttenhove
(Ludwig Institute for Cancer Research
Université Catholique de Louvain)
- Benoit J. Van den Eynde
(Ludwig Institute for Cancer Research
Université Catholique de Louvain
Walloon Excellence in Life Sciences and Biotechnology)
Abstract
Despite impressive clinical success, cancer immunotherapy based on immune checkpoint blockade remains ineffective in many patients due to tumoral resistance. Here we use the autochthonous TiRP melanoma model, which recapitulates the tumoral resistance signature observed in human melanomas. TiRP tumors resist immunotherapy based on checkpoint blockade, cancer vaccines or adoptive T-cell therapy. TiRP tumors recruit and activate tumor-specific CD8+ T cells, but these cells then undergo apoptosis. This does not occur with isogenic transplanted tumors, which are rejected after adoptive T-cell therapy. Apoptosis of tumor-infiltrating lymphocytes can be prevented by interrupting the Fas/Fas-ligand axis, and is triggered by polymorphonuclear-myeloid-derived suppressor cells, which express high levels of Fas-ligand and are enriched in TiRP tumors. Blocking Fas-ligand increases the anti-tumor efficacy of adoptive T-cell therapy in TiRP tumors, and increases the efficacy of checkpoint blockade in transplanted tumors. Therefore, tumor-infiltrating lymphocytes apoptosis is a relevant mechanism of immunotherapy resistance, which could be blocked by interfering with the Fas/Fas-ligand pathway.
Suggested Citation
Jingjing Zhu & Céline G. Powis de Tenbossche & Stefania Cané & Didier Colau & Nicolas van Baren & Christophe Lurquin & Anne-Marie Schmitt-Verhulst & Peter Liljeström & Catherine Uyttenhove & Benoit J., 2017.
"Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes,"
Nature Communications, Nature, vol. 8(1), pages 1-15, December.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00784-1
DOI: 10.1038/s41467-017-00784-1
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00784-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.